Shared mechanisms of statin uptake into the liver, metabolism, and pharmacology (e.g. with regards to hepatic processing and OATP transportation) suggest that, although different statins confer different absolute risks of myopathy, factors that increase the relative risk of myopathy would likely be shared. This evidence concerns the gene SLCO1A2 and myopathy.